169 related articles for article (PubMed ID: 10561021)
1. Preclinical and phase I and II trials of rituximab.
Maloney DG
Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
[TBL] [Abstract][Full Text] [Related]
2. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: an insider's historical perspective.
Grillo-López AJ
Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in indolent lymphoma: the single-agent pivotal trial.
McLaughlin P; Hagemeister FB; Grillo-López AJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):79-87. PubMed ID: 10561022
[TBL] [Abstract][Full Text] [Related]
5. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
8. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
9. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
10. High-dose rituximab therapy in chronic lymphocytic leukemia.
Keating M; O'Brien S
Semin Oncol; 2000 Dec; 27(6 Suppl 12):86-90. PubMed ID: 11226005
[TBL] [Abstract][Full Text] [Related]
11. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled antibody therapy of B-cell lymphomas.
Press OW
Semin Oncol; 1999 Oct; 26(5 Suppl 14):58-65. PubMed ID: 10561019
[TBL] [Abstract][Full Text] [Related]
14. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
15. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
Leonard JP; Goldenberg DM
Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
[TBL] [Abstract][Full Text] [Related]
19. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
20. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Czuczman MS
Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]